Catalyst Pharmaceuticals, Inc. (CPRX)
NEUTRALFondamentale
72
Prezzo
$-
Capitalizzazione
$3.85B
Parte 1 · Quanto vale l'azienda
Panoramica
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$597M
Ultimi 12 mesi (al 31/03/2026)
Utile Netto
$221M
Ultimi 12 mesi (al 31/03/2026)
Free Cash Flow
$172M
Patrimonio Netto Totale
$1.01B
Passività Totali
$3M
Rapporto di Liquidità
7.10
Copertura Interessi
-
Debito/EBITDA
0.01
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$47.09
Prezzo Attuale
-
Margine di Sicurezza
-
Range Fair Value
$30.61 - $63.58
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
17.42
ROE
24.5%
Rapporto P/B
3.80
P/FCF
-
Margine Lordo
86.0%
ROIC
20.8%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
20.8%
WACC
8.0%
ROIC − WACC
+12.8 pp
Il ROIC supera il costo del capitale: l'azienda sta creando valore per gli azionisti.
Criteri di Analisi Fondamentale
Superati (16)
- ROIC 20.8%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 44.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.6%
- Revenue Growth 5Y 37.7%
- Earnings Surprise avg 13.8%
- PEG Ratio 0.92
- Earnings Quality (OCF/NI) 0.94
- Net Margin Trend 37.1% vs 36.9%
Non superati (4)
- P/B Ratio 3.80
- DCF valuation (Unknown)
- Analyst Consensus 0% Buy
- Piotroski F-Score 1/9
Non disponibili (7)
- EPS data insufficient
- Historical price data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-Score
Preoccupazioni finanziarie serie
Qualità degli Utili
Moderata: qualche divario tra profitti e cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman | 78 |
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 64 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | 54 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 63 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 54 |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer | 60 |
| Ms. Mary Coleman | VP & Head of Investor Relations | - |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 61 |
| Mr. Gregg Russo | Chief Human Resources Officer | 62 |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 49 |
Rischio Audit
8
Rischio CdA
3
Rischio Compensi
8
Rischio Diritti Azionisti
4
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per CPRX, da Markets Gazette.
- 4/27/2026POSITIVEItaly’s Angelini Said to Explore Acquisition of Catalyst Pharma
Catalyst Pharmaceuticals Inc. is reportedly being explored for acquisition by Italian drugmaker Angelini Pharma. This potential deal signals significant interest in Catalyst's assets and market position, suggesting a possible premium valuation for shareholders. Angelini Pharma's exploration indicates a strategic move to expand its global reach, potentially through acquiring Catalyst's product pipeline or market access. Investors will be watching for further developments, as an acquisition could lead to a substantial uplift in Catalyst's stock price.
- 4/27/2026NEUTRALItaly’s Angelini Said to Explore Catalyst Pharma Acquisition
Angelini Pharma, an Italian drugmaker, is reportedly exploring the acquisition of US-based Catalyst Pharmaceuticals Inc. This potential deal is part of Angelini's strategy to broaden its international presence. Catalyst Pharmaceuticals, trading on the Nasdaq, specializes in treatments for rare autoimmune diseases. While the exploration is in its early stages and no deal is guaranteed, the news highlights potential consolidation within the pharmaceutical sector. Investors will monitor developments for any concrete offers and the strategic rationale behind such a move.
via Markets Gazette